• US$ 14M invested by Private Investors from 2012 (founders and VCs)
• US$ 5M invested by CSO and Innovation Authorities (Non dilutive Grants).
• In 2019 Max Herzberg and Yochai Richter acquired all shares of the VC group as a Management buy out
• From 2019 the Company is funded by them on a need to spend basis
• Going to Public Market for further major funding (Phase 2 and 3 for previous project and present application)
• Funding application to Horizon (EEC) : first application submitted on NMSC Phase 3 for VDA1102.

Special Announcement

Shares Repurchase Conditions
The Company announces today that the Board Members, employees and/or shareholders of Vidac Pharma Holding PLC (ISIN): GB00BM9XQ619, (the "Company") may exercise a Company’s shares repurchase in the amount of up to one hundred thousand Euros (the "Shares Repurchase"). Within the Shares Repurchase, it is planned to repurchase up to 100000 of the Company's shares, in the time from 20 October 2023 to 30 December 2023.
The Shares Repurchase will be carried out in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council dated April 16, 2014, in conjunction with the provisions of the Delegated Regulation (EU) 2016/1052 of the Commission dated March 8, 2016.
It is expected that the purchase price per share (excluding acquisition expenses) may not exceed or fall short by more than 10 per cent (%) of the market price of a share of the Company. The market price will be calculated as the last buy transaction published by the Exchange on the business day before or by default to the opening share value published by the Exchange every day as shown in the official price list of Hamburg or Stuttgart stock exchange respectively.
The Company will announce further details separately, including the trading volumes.
In addition, the Company will publish the announced transactions in the 'Investor Relations' section of its website (https://vidacpharma.com/en/investor-relations).